For more information, visit theconferenceforum.org
Many of the clinical trial delays and recruitment challenges in today's industry can be attributed to decisions made while designing the protocol and in the outsourcing strategy. Bringing clinical operations experts into the decision-making process can help proactively address some of the biggest challenges facing trials today. In this podcast, Raul Lima, MBA, EVP, Strategic Clinical Operations of inSeption Group, explains the difference between clinical development and clinical operations, misconceptions CMOs have about clinical operations and how to successfully navigate the complexities of clinical trial execution. For more information about inSeption Group, visit inSeptionGroup.com. For more information about the annual Chief Medical Officer Summit 360° and its affiliated editorials, podcasts and webcasts, please visit CMO360.org.
For more information, go to theconferenceforum.org
This podcast features a panel discussion on desgining and developing drug delivery and devices for LMICs with representatives from Gilead Sciences, the Bill & Melinda Gates Foundation, ApiJect and AbbVie From the 2024 PODD: Partnership Opportunities in Drug Delivery. The panelists discuss unique and compelling challenges of the last mile for LMICs, the role of pharma and medtech in the evolution of LMIC drug development, trends in the space, case studies of successful products and how to better consider cultural differences between LMICs and more developed markets. To learn more about the PODD conference, please visit PODDConference.com.
For more information, go to CRAACOevent.com or realtime-eclinical.com
For more information, visit theconferenceforum.org.
For more information, visit theconferenceforum.org
For more information, visit theconferenceforum.org
For more information, visit theconferenceforum.org
For more information, go to theconferenceforum.org
As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug development and how NanoViricides developed a nanotechnology with a different approach to develop and deliver antiviral drugs. Anil also presents an overview of the scientific and clinical development of NanoViricides lead program, NV-387 as well as potential applications in different indications. For more information about NanoViricides Incorporated, visit NanoViricides.com. For more information about the annual PODD drug delivery conference, please visit Drug-Delivery.org.
For more information, visit theconferenceforum.org
For more information, visit theconferenceforum.org
For more information, visit immuno-oncology360.org.
For more information, visit theconferenceforum.org.
For more information, visit theconferenceforum.org
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
For more information, go to theconferenceforum.org
For more information, go to theconferenceforum.org
For more information, visit patientsaspartners.org.